深圳市海王生物工程股份有限公司 2025年年度业绩预告

Performance Forecast - The company expects a net profit loss for the period from January 1, 2025, to December 31, 2025, with an estimated loss of approximately 110 million to 150 million yuan [1] - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by the accounting firm [1] Reasons for Performance Changes - The company is optimizing its business structure, which is expected to impact short-term performance. The focus is on increasing sales gross margin, ensuring asset safety, improving financing channels, and optimizing capital returns [1] - The company is evaluating long-term loss-making subsidiaries or business segments and plans to divest poor-performing assets through methods such as equity transfer, asset sales, and liquidation. This is expected to impact the net profit loss by approximately 110 million to 150 million yuan [1] Asset Impairment and Credit Losses - The company anticipates goodwill impairment of approximately 120 million to 150 million yuan, which is a significant decrease compared to previous periods, thus reducing the impact on current performance [2] - Credit impairment losses are expected to be around 150 million to 220 million yuan, with improvements in credit management and collection efforts. However, some public medical institutions have long-standing debt recovery issues that may exert pressure on overall credit impairment risk [2]